Serena Cima

Serena Cima

Auto-generated profile, based on publicly available information

Serena Cima

Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2009 in Gut
Verified
Journal Article
Closed access
PDF file
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
SGSara Galastri
Sara Galastri
PSPaolo Sacchi
Paolo Sacchi
SCSerena Cima
Serena Cima
ACAlessandra Caligiuri
Alessandra Caligiuri
FMFabio Marra
Fabio Marra
Objective: In patients with hepatitis C virus (HCV)/HIV co-infection, a faster progression of liver fibrosis to cirrhosis has been reported. In this study, an investigation was carried out to determine whether gp120, an HIV envelope protein, modulates the biology of human hepatic stellate cells (HSCs), key cell types in the pathogenesis of fibrosis. Methods: Myofibroblastic HSCs were isolated from normal human liver tissue. Gene expression was measured by real-time PCR. Cell migration was assessed in Boyden chambers. Intracellular signalling pathways were evaluated using phosphorylation-specific antibodies or by transfection of a reporter plasmid. Results: Transcripts for the chemokine receptors CCR5 and CXCR4, which bind gp120, were detectable in human HSCs. Upon exposure to M-tropic recombinant gp120, which binds CCR5, a significant increase in HSC chemotaxis was observed (1.6±0.3-fold, p=0.03). The effects of gp120 were prevented by protein inactivation. gp120 also resulted in a significant increase in secretion (1.5±0.3-fold, p=0.03) and gene expression (1.47±0.13-fold, p=0.02) of the proinflammatory chemokine monocyte chemoattractant protein-1, and in increased gene expression of tissue inhibitor of metalloprotease-1 and interleukin-6 (2.03±0.57-fold, p=0.02). gp120-induced migration required Akt activation. gp120 also induced activation of nuclear factor-κB (NF-κB) and p38 MAPK . Preincubation of HSCs with TAK779, a CCR5 receptor antagonist, prevented gp120-mediated chemotaxis and monocyte chemoattractant protein-1 secretion. Expression of CCR5 was detectable in areas of inflammation and fibrogenesis in liver biopsies of patients with HCV/HIV co-infection. Conclusions: This study shows that HIV gp120 modulates different aspects of HSC biology, including directional cell movement and expression of proinflammatory cytokines. These results identify a direct pathway possibly linking HIV infection with liver fibrogenesis via envelope proteins.

11 March 2016 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
PCPaola Columpsi
Paola Columpsi
PSPaolo Sacchi
Paolo Sacchi
VZValentina Zuccaro
Valentina Zuccaro
SCSerena Cima
Serena Cima
CSCristina Sarda
Cristina Sarda
Raffaele BrunoRaffaele Bruno
Raffaele Bruno

1 March 2015 in Digestive and Liver Disease
Verified
Journal Article
Closed access
PSPaolo Sacchi
Paolo Sacchi
SCSerena Cima
Serena Cima
MCMarta Corbella
Marta Corbella
GCGiuditta Comolli
Giuditta Comolli
ACAntonella Chiesa
Antonella Chiesa
Raffaele BrunoRaffaele Bruno
Raffaele Bruno

1 April 2016 in Antiviral Therapy
Verified
Journal Article
Closed access
ACAmedeo F Capetti
Amedeo F Capetti
GSGaetana Sterrantino
Gaetana Sterrantino
Maria Vittoria CossuMaria Vittoria Cossu
Maria Vittoria Cossu
GCGiovanni Cenderello
Giovanni Cenderello
ACAnna M Cattelan
Anna M Cattelan
LSLolita Sasset
Lolita Sasset
Background: Dolutegravir plus darunavir provide a high genetic barrier to HIV-1 resistance and are suitable for simple salvage regimens. Methods: All HIV-1-infected subjects treated with dolutegravir plus boosted darunavir dual therapy between March 2011 and September 2015 were included in an observational cohort. Data were collected at baseline and at weeks 4, 12, 24 and 48. Results: We enrolled 113 subjects. After week 24, one was lost at follow-up, one dropped out for grade 2 elevation of liver enzymes, one died from illicit drug abuse and one from cancer-related sepsis. The mean age was 51, 26.5% were female and 9.7% were non-Caucasian. Twenty had never experienced failure. A total of 99 had reverse-transcriptase (RT) mutations, 87 had protease inhibitor mutations and 12 had integrase strand transfer inhibitor (INSTI) mutations. Viraemic patients declined from baseline to week 24 from 43.4% to 6.2%, the remainder being due to high baseline viraemia or adherence issues. The proportion of subjects with viraemia 1–49 copies/ml remained at 20.4% while those in whom no virus was detected (NVD) increased from 36.3% to 73.5% by week 24. All the 47 subjects who had a 48-week follow-up had <50 copies/ml and 42 (89.4%) had NVD. 18 subjects had reduced sensitivity to darunavir (Stanford median score 15, range 15–40), but none rebounded, 6 having a 24-week and 7 a 48-week follow-up. The median variation in serum creatinine was -0.01 (range +0.2 to -0.21) mg/dl. Conclusions: This dual regimen provides a simple salvage regimen and proved safe and effective in this cohort.

1 July 2011 in Digestive and Liver Disease
Verified
Journal Article
Closed access
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
PSPaolo Sacchi
Paolo Sacchi
SCSerena Cima
Serena Cima
LMLaura Maiocchi
Laura Maiocchi
SPSavino F.A. Patruno
Savino F.A. Patruno
GFGaetano Filice
Gaetano Filice

10 January 2012 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
PSPaolo Sacchi
Paolo Sacchi
SCS. Cima
S. Cima
LMLaura Maiocchi
Laura Maiocchi
SNS. Novati
S. Novati
SFSTEFANO FAGIUOLI
STEFANO FAGIUOLI